[VCYT] Veracyte, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Medical Specialities

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 7.67 Change: 0.32 (4.35%)
Ext. hours: Change: 0 (0%)

chart VCYT

Refresh chart

Strongest Trends Summary For VCYT

VCYT is in the medium-term up 43% in 1 month and up 63% above S&P in 4 months and up 173% above S&P in 1 year.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Veracyte, Inc. operates as a diagnostics company in the field of molecular cytology to enhance patient outcomes and lower healthcare costs. It provides Afirma Thyroid FNA Analysis, a solution that consists of its Gene Expression Classifier, which helps physicians in reducing unnecessary diagnostic surgeries for patients with thyroid nodules. The company is also developing Afirma Malignancy Classifiers for rare forms of thyroid cancer or metastases to the thyroid that is intended to inform surgical strategy; and idiopathic pulmonary fibrosis and nodules suspicious products for lung cancer. It serves endocrinologists, radiologists, and head and neck specialists. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 29.28% Sales Growth - Q/Q-8.04% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-55.05% ROE-86.4% ROI
Current Ratio2.38 Quick Ratio2.12 Long Term Debt/Equity0.25 Debt Ratio0.4
Gross Margin58.11% Operating Margin-71.51% Net Profit Margin-72.28% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities90 K Cash From Investing Activities-440 K Cash From Operating Activities-8.87 M Gross Profit6.65 M
Net Profit-7.61 M Operating Profit-7.55 M Total Assets55.06 M Total Current Assets33.69 M
Total Current Liabilities14.15 M Total Debt4.95 M Total Liabilities19.98 M Total Revenue11.22 M
Technical Data
High 52 week15.2 Low 52 week5.39 Last close15.2 Last change4.54%
RSI78.52 Average true range0.89 Beta1.22 Volume63.83 K
Simple moving average 20 days20.59% Simple moving average 50 days18.89% Simple moving average 200 days52.33%
Performance Data
Performance Week26.67% Performance Month27.62% Performance Quart59.5% Performance Half46.44%
Performance Year131% Performance Year-to-date20.83% Volatility daily4.1% Volatility weekly9.17%
Volatility monthly18.79% Volatility yearly65.09% Relative Volume207.13% Average Volume456.37 K
New High New Low

News

2019-01-09 16:30:00 | Veracyte to Present at the 21st Annual Needham Growth Conference

2019-01-03 09:54:31 | Can the nose point the way to early lung cancer detection? This Peninsula company's Big Pharma deal aims to find out

2019-01-03 07:00:00 | Veracyte Announces Strategic Collaboration with Johnson & Johnson Innovation in Battle Against Lung Cancer

2019-01-02 17:54:00 | Veracyte to Present at the 37th Annual J.P. Morgan Healthcare Conference

2018-12-05 07:30:00 | Veracyte Announces Expansion of Envisia Genomic Classifier Early Access Program

2018-11-23 08:55:00 | Investor Expectations to Drive Momentum within Cel-Sci, DGSE Companies, Veracyte, China Pharma, Barnwell Industries, and Silvercrest Asset Management Group — Discovering Underlying Factors of Influence

2018-11-09 08:30:00 | Veracyte to Present at the Canaccord Genuity Medical Technologies & Diagnostics Forum

2018-11-08 16:24:00 | Veracyte Announces Publication of Data Demonstrating “Real World” Performance of Afirma GSC in Thyroid Cancer Diagnosis

2018-11-01 16:30:02 | Veracyte Raised Its Financial Guidance after Q3 2018

2018-11-01 15:00:02 | A Financial Overview of Veracyte for November

2018-11-01 13:26:13 | Veracyte Stock Witnesses Solid Growth after Its Q3 Results

2018-10-31 12:00:00 | 3 Healthcare Stocks Leading New Industry Trends

2018-10-30 17:27:00 | Here's Why Veracyte Jumped 22.5% Higher Today

2018-10-30 04:04:16 | Edited Transcript of VCYT earnings conference call or presentation 29-Oct-18 8:30pm GMT

2018-10-29 18:10:10 | Veracyte VCYT Reports Q3 Loss, Tops Revenue Estimates

2018-10-29 17:07:31 | Veracyte: 3Q Earnings Snapshot

2018-10-29 16:05:00 | Veracyte Announces Third Quarter 2018 Financial Results

2018-10-29 07:44:08 | Q3 Earnings Preview For Veracyte

2018-10-22 10:31:02 | Veracyte VCYT Q3 Earnings Preview: Here's What to Look Out For

2018-10-15 16:20:00 | Veracyte to Host Conference Call and Webcast to Discuss Third Quarter 2018 Financial Results on Monday, October 29, 2018

2018-10-09 16:05:00 | Veracyte Announces Presentation of “Real World” Clinical Utility Data at CHEST 2018 Showing Percepta Classifier Reduces Invasive Procedures in Lung Cancer Diagnosis

2018-10-08 16:05:00 | Veracyte Announces Presentation of Data Confirming Envisia Genomic Classifier’s Ability to Improve Diagnosis of Idiopathic Pulmonary Fibrosis

2018-10-06 13:50:00 | Veracyte Announces that New Data from Multiple Studies Demonstrate “Real World” Performance of Afirma GSC and Xpression Atlas in Thyroid Cancer Diagnosis

2018-10-05 20:38:07 | Versant Venture Management, LLC Buys Veracyte Inc

2018-09-27 16:05:00 | Veracyte to Present at the Cantor Fitzgerald Global Healthcare Conference

2018-09-27 08:15:00 | Veracyte Announces New Data Reinforcing Clinical Value of Genomic Tests In Lung Disease Diagnoses to Be Presented at CHEST Annual Meeting 2018

2018-09-26 08:15:00 | Veracyte Announces Multiple Studies to Be Presented at ATA Annual Meeting Demonstrating “Real World” Performance of Afirma GSC and Xpression Atlas in Thyroid Cancer Diagnosis

2018-09-10 15:18:27 | Is Veracyte Inc NASDAQ:VCYT A Healthcare Industry Laggard Or Leader?

2018-08-31 08:29:45 | The Daily Biotech Pulse: FDA Blessings for Merck's HIV Drug Combo, Veracyte's Test Gets Medicare Coverage

2018-08-30 16:06:00 | Veracyte Achieves Major Medicare Milestone for the Envisia Genomic Classifier

2018-08-30 08:15:00 | Veracyte to Present at the Morgan Stanley 16th Annual Global Healthcare Conference

2018-08-29 16:05:00 | Veracyte Names Angeline McCabe as Vice President, Investor Relations and Corporate Communications

2018-08-13 08:45:12 | Implied Volatility Surging for Veracyte VCYT Stock Options

2018-07-30 16:15:00 | Veracyte to Present at the Canaccord Genuity 38th Annual Growth Conference

2018-07-30 12:15:00 | Veracyte Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

2018-07-30 07:26:11 | Zacks.com featured highlights include: OFG, Northern Oil, Sunrun, Cerus and Veracyte

2018-07-27 08:41:12 | 5 Breakout Stocks Offering Stellar Returns

2018-07-25 20:29:00 | Veracyte Announces Pricing of Public Offering of 5,000,000 Shares of Common Stock

2018-07-25 08:41:11 | Benzinga's Daily Biotech Pulse: Merck's Keytruda Found Effective, Nabriva To Acquire Zavante, FDA Denies Agile

2018-07-25 08:20:15 | Veracyte Raised Its Financial Guidance after Its Q2 2018 Results

2018-07-24 21:13:31 | Edited Transcript of VCYT earnings conference call or presentation 23-Jul-18 8:30pm GMT

2018-07-24 16:01:00 | Veracyte Announces Proposed Public Offering of Common Stock

2018-07-23 16:09:40 | Veracyte: 2Q Earnings Snapshot

2018-07-23 16:05:00 | Veracyte Announces Second Quarter 2018 Financial Results

2018-07-23 14:30:00 | Veracyte Inc to Host Earnings Call

2018-07-23 08:47:20 | Earnings Preview: Veracyte

2018-07-09 16:05:00 | Veracyte to Host Conference Call and Webcast to Discuss Second Quarter 2018 Financial Results on Monday, July 23, 2018

2018-07-02 08:15:00 | Veracyte Chairman and CEO to Speak at MedCity CONVERGE

2018-06-25 08:15:00 | Veracyte Named a San Francisco Bay Area “Top Workplace” for Fifth Consecutive Year

2018-06-21 07:55:00 | New Research: Key Drivers of Growth for Nicolet Bankshares, Vitamin Shoppe, Aethlon Medical, Barrett Business Services, Veracyte, and TPG Specialty Lending — Factors of Influence, Major Initiatives and Sustained Production